Industry Has 45 Days To Implement DEA’s Rescheduling Of Hydrocodone Combo Products
This article was originally published in The Pink Sheet Daily
Executive Summary
DEA reschedules hydrocodone combination products from Schedule III to Schedule II with 45-day effective date; industry had requested more time to implement handling requirements.
You may also be interested in...
Hydrocodone Combination Up-scheduling Marches Forward Despite FDA Ambivalence
FDA’s Drug Safety and Risk Management Advisory Committee votes 19-10 to move the opioid drugs to the more restrictive Schedule II because their abuse potential is similar to other drugs already that already have the controlled substances designation.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.
Current Pathways For Rare Disease Drugs Are Not Optimal, US FDA’s Califf Says
Anticipating a ‘tsunami of therapies’ for rare diseases, commissioner says the agency will have to think of creative approaches and employ regulatory flexibility for them. FDA considers copying the oncology center’s Project Facilitate for expanded access to other diseases.